risk communication in nda (new drug application) massie ikeda md, phd chief medical reviewer...
TRANSCRIPT
![Page 1: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/1.jpg)
Risk Communication inNDA (New Drug Application)
Massie Ikeda MD, PhD
Chief Medical Reviewer
Pharmaceuticals and Medical Devices Agency
![Page 2: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/2.jpg)
Standard Disclaimer
• This is not an official PMDA/MHLW guidance or policy statement.
• No official support of endorsement by PMDA/MHLW is intended or should be inferred.
![Page 3: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/3.jpg)
Today’s TopicsWhy do we need:
1. Clinical trials ?
2. Regulatory body ?
3. Risk communication ?
![Page 4: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/4.jpg)
“New Drug” reminds you of・・・
• Newspaper Articles
• Tough Diseases: HIV, Cancer
• High-Techs in Medicine
• Severe Adverse Effects
• Mega Pharma Companies
• Clinical Trials
![Page 5: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/5.jpg)
Why do we need clinical trials ?
• Is it OK with animal data only ?
• Let safe drugs only go into the market?• Are clinical trials dangerous?• Let us leave to the doctors?• Why do we need placebo ?
![Page 6: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/6.jpg)
We humans needour own human data.
You never want dog or cat food on your dinner menu.
The same with your drug.
![Page 7: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/7.jpg)
Are you happy withalternative medicine only?
You probably need drugs whose data have been scientifically
reviewed.
![Page 8: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/8.jpg)
Human Experiment Era
![Page 9: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/9.jpg)
Today’s TopicsWhy do we need:
1. Clinical trials ?
2. Regulatory body ?
3. Risk communication ?
![Page 10: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/10.jpg)
Benchmarking of Drugs: Who does it ?
![Page 11: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/11.jpg)
Independent BodyRegulatory Authority
•PMDA
•FDA
•EMEAIn your home country?
![Page 12: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/12.jpg)
MHLW JPMA
FDA
PhRMA
EMEA
EFPIA
ICH
![Page 13: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/13.jpg)
ICHInternational Conference on Harmonisation of Technical Requirements for Registrat
ion of Pharmaceuticals for Human Use
![Page 14: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/14.jpg)
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
• Japan, USA, EU• To make common regulations and share data
on clinical trials• It is not an academic conference• Working on drugs but not on devices
![Page 15: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/15.jpg)
各種分科会があるTuesday, 8 June 2004Time Code Topic8:00 am - 9:00 am CTD-CG CTD Implementation Coordination Group
9:00 am - 5:00 pmICG Industry Coordination Group9:00 am - 5:00 pmRegulators Regulators Meeting
9:00 am - 5:00 pmM1P MedDRA PtCWG9:00 am - 5:00 pmM2 Electronic Standards for Transfer of Information (eCTD)9:00 am - 5:00 pmE2B EWG Electronic Submission in Individual Case Safety Reports9:00 am -10:30 amS7B/ E14 Safety Pharmocology Qt Prolongation/ Clinical Qt Prolongation10:30 am - 5:00 pmS7B Safety Pharmocology Qt Prolongation9:00 am - 5:00 pmS8 Immunotoxicology10:30 am - 5:00 pmE14 Clinical Qt Prolongation12:00 pm - 5:00 pmQ4 Pharmacopoeial Harmonization9:00 am - 5:00 pmQ5E Comparability of Biotechnological/ Biological Products9:00 am -10:30 amQ8/ Q9/ QSGMP Plenary10:30 am - 5:00 pmQ8 Pharmaceutical Development10:30 am - 5:00 pmQ9 Risk Management9:00 am - 5:00 pmQS Quality Systems12:00 pm - 5:00 pmPDG Pharmacopoeial Discussion Group9:00 am- 12:00 pmPDG/ Q4 Pharmacopoeial Discussion Group/ Pharmacopoeial Harmonization9:00 am - 5:00 pmGT Gene therapy
![Page 16: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/16.jpg)
![Page 17: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/17.jpg)
QE5分科会参加者名簿
![Page 18: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/18.jpg)
What is ICH E5 for?
• For providing good drugs faster to everybody in the world, especially ICH resions.
• It is not intended to bypass important domestic clinical studies.
![Page 19: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/19.jpg)
Importance of ethnic differences
• Intrinsic
PK/PD, genetic analysis (in future), etc.
• Extrinsic
differences in clinical practice, etc.
![Page 20: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/20.jpg)
Ethnic Difference in Alcohol Dehydrogenase
Alcohol Welcome Acceptable HateADH Active Partial DeficientJapanese 56 40 4Whites 100 0 0
![Page 21: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/21.jpg)
Warfarin for NVAF
Japan
US
![Page 22: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/22.jpg)
Coagulation factor mutation
![Page 23: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/23.jpg)
SARS & HLA typing
![Page 24: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/24.jpg)
An example of difference among Asians
SARS & HLA typing
HLAB46Jpn 4.4Krn 4.4Vtnm 13.2Sngp 15.1Kanton 15.4
![Page 25: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/25.jpg)
Importance of ethnic differences
• Intrinsic
PK/PD, genetic analysis (in future), etc.
• Extrinsic
differences in clinical practice, etc.
![Page 26: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/26.jpg)
Japan USA
MHLW approval
Universal health insurance coverage国民皆保険
FDA approval
Health insurance system C
Health insurance system B
Health insurance system A
![Page 27: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/27.jpg)
CTD(Common Technical Document)
as CV of the Drug
Our common ground to analyse the benefits and risks of the drug
![Page 28: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/28.jpg)
CTD as a CV of the new drug
Disclosure & accountability is essential.
CURRICULUM VITAE FORMATFORTENURE AND PROMOTION DOSSIERS
NAME: ___________________________________________________________ (Last)(First)(Initial)EDUCATION: UNDERGRADUATE: ________________________________________ GRADUATE: _______________________________________________POST DOCTORAL: _________________________________________
ACADEMIC APPOINTMENTS (inclusive dates):
OTHER APPOINTMENTS AND PROFESSIONAL CONSULTANTSHIPS (including other remunerated employment):
LICENSURE AND CERTIFICATION:
![Page 29: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/29.jpg)
CTD as CV of the Drug
•Disclosure & Accountability•It is not a brochure or propaganda•Disclosure of not only the benefit•Explain why
•The drug is indicated to the target•The drug overcomes the rivals
![Page 30: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/30.jpg)
CTD is
CV of the drug applicationCommon ground of
communicationKey for disclosure and
accountability
![Page 31: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/31.jpg)
Time to approval PMDEC/MHLW NDA FDA (CDER)
Standard NDAapproved year
approvals
median months to approval
approvals
median months to approval
1997 40 33.6 101 15.01998 58 36.6 65 12.01999 71 30.6 55 13.82000 84 18.8 78 12.02001 57 15.5 56 14.02002
67 15.352 15.8
![Page 32: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/32.jpg)
Today’s TopicsWhy do we need:
1. Clinical trials ?
2. Regulatory body ?
3. Risk communication ?
![Page 33: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/33.jpg)
Our Mission
BenefitRisk
![Page 34: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/34.jpg)
No bad news is bad news
when people are not aware of its shadow.
![Page 35: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/35.jpg)
Why not share the bad news ?
because it comes out sooner or later.
![Page 36: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/36.jpg)
Difficulties in risk communication
LiabilityConflicts of interestsUncertainty & Variety
Adverse events: Drug-related on notOne understands A causes B but others do notChanges as time goes by
![Page 37: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/37.jpg)
But we have to share bad news because:
It will come out, anyway.Early intervention before disasterStay calm & avoid panicTo correct the system effectivelyTo make no scapegoat
![Page 38: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/38.jpg)
Common Flaws in NDA
• Focus only on efficacy instead of safety
• Insisting on safety:– No significant difference compared with the
placebo– No causal relationship– Very low frequency– No similar case in PMS outside Japan
![Page 39: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/39.jpg)
Our Common Aim-Regulatory Authority & Pharma Co-
Good Drugs for People
Not conflict but Cooperation
![Page 40: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/40.jpg)
The sooner, the better ?The lessons from Rofecoxib ( Viox
x)• Cox2 Inhibitor
– Stomach-friendly super aspirin– FDA approved in May 1999
• Voluntary withdrawal in September 2004
• Due to an increased risk of cardiovascular events (including heart attack and stroke)
![Page 41: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/41.jpg)
Stop Confrontation
Drug Co.
Citizens
Government
Media
![Page 42: Risk Communication in NDA (New Drug Application) Massie Ikeda MD, PhD Chief Medical Reviewer Pharmaceuticals and Medical Devices Agency](https://reader035.vdocument.in/reader035/viewer/2022062321/56649dc75503460f94abbd91/html5/thumbnails/42.jpg)
Future Issues
• Synthesizing data on safety– Pharmacovigilance system– Harmonization on safety data
• Safety and order-made medicine, e.g. SNP
• Media Relation– Risk Communication with lay press & people